Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.76 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.76 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.76 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.76 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.76 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.76 |
| ▸ | GABRP | O00591 | 2/20 | 0.76 |
| ▸ | GABRD | O14764 | 2/20 | 0.76 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.76 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.76 |
| ▸ | GABRE | P78334 | 2/20 | 0.76 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.76 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.76 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.76 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376244 | 0.87 | CHRM1 (0.73) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13746712 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29743048 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29361251 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL38899 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL29369721 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL13747803 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL5501860 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL9834407 | 0.85 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Clonazepam SCHEMBL31321724 | 0.85 | GABRA1 (0.98) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20100197516-A1 | DETECHIP: MOLECULAR COLOR AND FLUORESCENT SENSORY ARRAYS FOR SMALL MOLECULES | HOLMES ANDREA | 2010-08-05 | — | — | US | disclosed |
| US-20100197516-A1 | DETECHIP: MOLECULAR COLOR AND FLUORESCENT SENSORY ARRAYS FOR SMALL MOLECULES | HOLMES ANDREA | 2010-08-05 | — | — | US | disclosed |
| WO-2010081036-A2 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0801651-B1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | HOFFMANN LA ROCHE (CH) | 2001-07-11 | — | — | EP | disclosed |
| US-6174881-B1 | USED AS ANXIOLYTIC AND/OR ANTICONVULSANT AND/OR MUSCLE RELAXANT AGENTS; SEDATIVES OR HYPNOSIS; WATER-SOLUBLE AMINE SALTS; FAST-ACTING | HOFFMAN-LA ROCHE INC. | 2001-01-16 | — | — | US | disclosed |
| WO-1996020941-A1 | HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-07-11 | — | — | WO | disclosed |
| US-4472435-A | HYPOTENSIVE AGENT, ALDOSTERONE ANTAGONIST, AND TREATMENT OF HEPATITIS | HOFFMAN-LA ROCHE INC. (US) | 1984-09-18 | — | — | US | disclosed |
| US-4440685-A | MUSCLE RELAXANTS, SEDATIVES, ANTICONVULSANTS | HOFFMANN-LA ROCHE INC. (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0045450-B1 | BENZOPHENONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-02-15 | — | — | EP | disclosed |
| US-4349476-A | IMIDAZO/1,5-A//1,4) BENZO-, THIENO-, OR PYRAZOLODIAZEPINES FROM DERIVATIVES OF BENZO-, THIENO- OR PYRAZOLODIAZEPINE | HOFFMANN-LA ROCHE INC. (US) | 1982-09-14 | — | — | US | disclosed |
| US-4349477-A | IMIPAZO/1,5-A//1,4/BENZO-, THIENO- OR PYRAZOLODIAZEPINES FROM 2-DIMORPHOLINOPHOSPHONATES OF BENZO-, THIENO- OR PYRAZOLODIAZEPINES | HOFFMANN-LA ROCHE INC. (US) | 1982-09-14 | — | — | US | disclosed |
| US-4347365-A | ANTICONVULSANTS, MUSCLE RELAXANTS, SEDATIVES | HOFFMANN-LA ROCHE INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347364-A | INTERMEDIATES THEREFOR | HOFFMANN-LA ROCHE INC. (US) | 1982-08-31 | — | — | US | disclosed |
| EP-0045450-A1 | Benzophenone derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
| US-4307237-A | ANTICONVULSANTS, SEDATIVES, MUSCLE RELAXANTS | HOFFMANN-LA ROCHE INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4280957-A | Imidazodiazepines and processes therefor | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | disclosed |
| US-4118386-A | Synthesis of imidazo[1,5-a]diazepine-3-carboxylates | HOFFMANN-LA ROCHE INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-3996209-A | Process for preparing benzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3956492-A | SEDATIVES, MUSCLE RELAXANTS, TRANQUILIZERS, ANTICONVULSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | GABRA1 879/4885GABRA5 1254/4885GABRA3 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.